2021 Journal Article Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocolUllman, Amanda J., August, Deanne, Kleidon, Tricia, Walker, Rachel, Marsh, Nicole M., Bulmer, Andrew, Pearch, Benjamin, Runnegar, Naomi, Schults, Jessica A., Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Southam, Katrina, Gibson, Victoria, Byrnes, Joshua, Ware, Robert S., Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M. and Harris, Patrick N. A. (2021). Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol. BMJ Open, 11 (4) e042475, 1-7. doi: 10.1136/bmjopen-2020-042475 |
2021 Journal Article Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y |
2021 Journal Article SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patientsChen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523 |
2021 Journal Article Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trialPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370 |
2021 Journal Article The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograftRees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2 |
2021 Journal Article The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3 |
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
2021 Journal Article Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein ReportingSmith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001 |
2020 Journal Article Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devicesEllis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780 |
2020 Journal Article A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, Phoebe Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2020). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 136 (Supplement 1), 4-5. doi: 10.1182/blood-2020-138394 |
2020 Journal Article Physical activity in people with multiple myeloma: associated factors and exercise program preferencesNicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277 |
2020 Journal Article Bortezomib, melphalan, and dexamethasone for light-chain amyloidosisKastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, Maria Teresa, Kwok, Fiona, Mollee, Peter, Hajek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schonland, Stefan O., Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, Maria-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A., Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Erik Johnsen, Hans, Merlini, Giampaolo and Palladini, Giovanni (2020). Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. Journal of Clinical Oncology, 38 (28), 3252-3260. doi: 10.1200/JCO.20.01285 |
2020 Journal Article Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trialMollee, P., Okano, S., Abro, E., Looke, D., Kennedy, G., Harper, J., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Jones, M. (2020). Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial. Journal of Hospital Infection, 106 (2), 335-342. doi: 10.1016/j.jhin.2020.07.021 |
2020 Journal Article HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patientsBurgess, M., Chen, U. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2020). HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. Oncogene, 39 (35), 5756-5767. doi: 10.1038/s41388-020-01394-w |
2020 Journal Article Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLLBurgess, Melinda, Chen, Yu Chen Enya, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas A. (2020). Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. Leukemia and Lymphoma, 61 (11), 1-5. doi: 10.1080/10428194.2020.1775211 |
2020 Journal Article Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceWeinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A and Teh, Benjamin W (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Medical Journal of Australia, 212 (10) mja2.50607, 481-489. doi: 10.5694/mja2.50607 |
2020 Journal Article Bortezomib use and outcomes for the treatment of multiple myelomaLoke, Crystal, Mollee, Peter, McPherson, Ian, Walpole, Euan, Yue, Mimi, Mutsando, Howard, Wong, Phillip, Weston, Helen, Tomlinson, Ross and Hollingworth, Samantha (2020). Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal, 50 (9) imj.14886, 1059-1066. doi: 10.1111/imj.14886 |
2020 Journal Article A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupMaqbool, M. Gohar, Tam, Constantine S., Morison, Ian M., Simpson, David, Mollee, Peter, Schneider, Hans, Chan, Henry, Juneja, Surender, Harvey, Yasmin, Nath, Lakshmi, Hissaria, Pravin, Prince, H. Miles, Wordsworth, Helen, Opat, Stephen and Talaulikar, Dipti (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 52 (2), 167-178. doi: 10.1016/j.pathol.2019.11.002 |
2020 Journal Article Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolomeMohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A. and Hill, Michelle M. (2020). Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PloS One, 15 (1) e0227455, e0227455. doi: 10.1371/journal.pone.0227455 |
2019 Journal Article Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic statusHarwood, Matthew, Dunn, Nathan, Moore, Julie, Mollee, Peter and Hapgood, Greg (2019). Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leukemia & Lymphoma, 61 (3), 1-7. doi: 10.1080/10428194.2019.1688322 |